{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:18:52Z","timestamp":1791854332554,"version":"4.3.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ad.2024.01.009","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T18:01:47Z","timestamp":1705168907000},"page":"T265-T279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review"],"prefix":"10.1016","volume":"115","author":[{"given":"M.","family":"Mansilla-Polo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Morgado-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.01.009_bib0435","doi-asserted-by":"crossref","first-page":"e12932","DOI":"10.1111\/dth.12932","article-title":"Biologics in dermatology: What does the future hold?","volume":"32","author":"Yavuz","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2024.01.009_bib0440","doi-asserted-by":"crossref","first-page":"421","DOI":"10.23736\/S0392-0488.20.06684-5","article-title":"Apremilast for psoriasis treatment","volume":"155","author":"Carrascosa","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.01.009_bib0445","doi-asserted-by":"crossref","first-page":"e14261","DOI":"10.1111\/dth.14261","article-title":"Apremilast in dermatology: A review of literature","volume":"33","author":"Nassim","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2024.01.009_bib0450","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40257-023-00780-w","article-title":"Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged \u2265 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study","volume":"24","author":"Eichenfield","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0455","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s40265-015-0463-1","article-title":"Roflumilast: A Review in COPD","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ad.2024.01.009_bib0460","first-page":"ljad182","article-title":"Once-daily roflumilast foam 0.3% for scalp and body psoriasis: A randomized, double-blind, vehicle-controlled stage 2b study","author":"Kircik","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0465","first-page":"e230846","article-title":"Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Stage 2a Randomized Clinical Trial","author":"Zirwas","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0470","article-title":"A Proof of Concept Stage II Study With the PDE4 Inhibitor Roflumilast in Patients With (Amnestic) Mild Cognitive Impairment (MCI) or Mild Dementia","year":"2022","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0475","author":"Takeda","year":"2016","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0480","article-title":"The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients. Proof-of-Concept, Randomized, Double-Blind Placebo-Controlled Trial","author":"Abdallah","year":"2023","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0485","article-title":"Efficacy of Roflumilast in Prevention of Peripheral Neuropathy","author":"Mansour","year":"2023","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0490","article-title":"Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Baclofen, Roflumilast, Memantine, and Placebo in Fragile X Syndrome","year":"2023","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0495","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00213-017-4631-8","article-title":"The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL\/6J mice","volume":"234","author":"Liu","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ad.2024.01.009_bib0500","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.01.009_bib0505","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1465-9921-12-140","article-title":"Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects","volume":"12","author":"Gauvreau","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.ad.2024.01.009_bib0510","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/ecp.13.2","article-title":"The asthma-chronic obstructive pulmonary disease overlap syndrome: Pharmacotherapeutic considerations","volume":"6","author":"Louie","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ad.2024.01.009_bib0515","unstructured":"Effect of roflumilast on cough and sputum in patients with severe or very severe chronic obstructive pulmonary disease (COPD) receiving inhaled combination therapy: Evaluation of the exacerbation of chronic pulmonary disease tool-patient reported outcomes (exact-pro) subdomain scores | Cochrane Library s.f."},{"key":"10.1016\/j.ad.2024.01.009_bib0520","article-title":"Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Non-cystic Fibrosis Bronchiectasis: a Cross-over, Unicentric, Double-blind and Placebo-controlled Study","year":"2020","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0525","doi-asserted-by":"crossref","first-page":"101978","DOI":"10.1016\/j.pupt.2020.101978","article-title":"Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19","volume":"66","author":"Jabaris","year":"2021","journal-title":"Pulm Pharmacol Ther."},{"key":"10.1016\/j.ad.2024.01.009_bib0530","first-page":"1165","article-title":"Roflumilast Altana Pharma","volume":"3","author":"Reid","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.ad.2024.01.009_bib0535","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/0091270006294529","article-title":"Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor","volume":"47","author":"Bethke","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ad.2024.01.009_bib0540","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ad.2024.01.009_bib0545","unstructured":"CIMA. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Roflumilast. Ficha t\u00e9cnica. Disponible en: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/85529\/85529_ft.pdf"},{"key":"10.1016\/j.ad.2024.01.009_bib0550","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","article-title":"Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease","volume":"163","author":"Rabe","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ad.2024.01.009_bib0555","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1177\/0091270006291621","article-title":"Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects","volume":"46","author":"Hauns","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ad.2024.01.009_bib0560","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.3390\/molecules27154964","article-title":"An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022","volume":"27","author":"Crocetti","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ad.2024.01.009_bib0565","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ad.2024.01.009_bib0570","first-page":"149","article-title":"Roflumilast (daliresp): A novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease","volume":"37","author":"Baye","year":"2012","journal-title":"P T"},{"key":"10.1016\/j.ad.2024.01.009_bib0575","series-title":"Goodman & Gilman's: The Pharmacological Basis of Therapeutics","article-title":"Pharmacodynamics: Molecular Mechanisms of Drug Action","author":"Blumenthal","year":"2017"},{"issue":"Suppl 2","key":"10.1016\/j.ad.2024.01.009_bib0580","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0014-2565(11)70008-X","article-title":"Phosphodiesterase-4 inhibitors: Roflumilast [Article in Spanish]","volume":"211","author":"Izquierdo Alonso","year":"2011","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.ad.2024.01.009_bib0585","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ad.2024.01.009_bib0590","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archderm.1973.01620160019003","article-title":"Defects and deficiency of adenyl cyclase in psoriatic skin","volume":"107","author":"Wright","year":"1973","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0595","doi-asserted-by":"crossref","first-page":"1057083","DOI":"10.3389\/fphar.2022.1057083","article-title":"Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules","volume":"13","author":"Bondarev","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ad.2024.01.009_bib0600","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.reuma.2016.07.011","article-title":"Selective Phosphodiesterase Inhibitors: A New Therapeutic Option in Inflammation and Autoimmunity","volume":"12","author":"Hern\u00e1ndez-Fl\u00f3rez","year":"2016","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.ad.2024.01.009_bib0605","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.molimm.2009.03.018","article-title":"The adenylyl cyclase-cAMP system suppresses TARC\/CCL17 and MDC\/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes","volume":"46","author":"Qi","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ad.2024.01.009_bib0610","first-page":"CD002309","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","author":"Chong","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ad.2024.01.009_bib0615","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0140-6736(12)60304-3","article-title":"Side-effects of roflumilast","volume":"379","author":"Gupta","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2024.01.009_bib0620","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4143\/crt.2020.1371","article-title":"Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed\/Refractory Patients with Diffuse Large B-Cell Lymphoma","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ad.2024.01.009_bib0625","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.7150\/jca.21783","article-title":"Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer","volume":"8","author":"Domvri","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.ad.2024.01.009_bib0630","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/dom.12839","article-title":"The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism","volume":"19","author":"M\u00f6llmann","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ad.2024.01.009_bib0635","article-title":"An Exploratory Study to Evaluate the Effects of Roflumilast on Insulin Sensitivity and Metabolic Parameters in Prediabetic Overweight and Obese Individuals","year":"2018","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0640","year":"2016","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0645","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1753465812466167","article-title":"Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis","volume":"7","author":"Oba","year":"2013","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ad.2024.01.009_bib0650","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A stage III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0655","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.lanepe.2023.100639","article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis\u2014a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ad.2024.01.009_bib0660","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/14740338.2016.1199683","article-title":"Drug safety evaluation of roflumilast for the treatment of COPD: A meta-analysis","volume":"15","author":"Rogliani","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ad.2024.01.009_bib0665","article-title":"Long-Term Post-Marketing Observational Study of the Safety of Roflumilast","author":"AstraZeneca","year":"2022","journal-title":"clinicaltrials.gov;"},{"key":"10.1016\/j.ad.2024.01.009_bib0670","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/MJT.0000000000000465","article-title":"Treating 2 Diseases With 1 Drug: PDE-4 Inhibitor for COPD and Psoriasis","volume":"24","author":"Michels","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.ad.2024.01.009_bib0675","doi-asserted-by":"crossref","first-page":"734","DOI":"10.36849\/JDD.2020.5370","article-title":"Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Stage 1\/2a Randomized. Controlled Study","volume":"19","author":"Papp","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0680","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40257-022-00739-3","article-title":"Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Stage 2b Trial","volume":"24","author":"Stein Gold","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0685","author":"AstraZeneca","year":"2016","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0690","doi-asserted-by":"crossref","first-page":"139","DOI":"10.36849\/JDD.7295","article-title":"The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Stage 2 Proof of Concept Study","volume":"22","author":"Gooderham","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0695","article-title":"A Stage 1\/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects With Chronic Hand Eczema","year":"2022","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0700","article-title":"Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea","author":"Draelos","year":"2023","journal-title":"clinicaltrials.gov;"},{"key":"10.1016\/j.ad.2024.01.009_bib0705","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2023.04.001","article-title":"Roflumilast enhances the melanogenesis and attenuates oxidative stress-triggered damage in melanocytes","volume":"110","author":"Chen","year":"2023","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.ad.2024.01.009_bib0710","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/bjd.20602","article-title":"Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy","volume":"185","author":"Egeberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0715","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1111\/jdv.18647","article-title":"Long-term clearance of severe plaque psoriasis with oral roflumilast","volume":"37","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.01.009_bib0720","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bjd.21744","article-title":"Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy","volume":"187","author":"Ring","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0725","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bjd.21044","article-title":"Rapid improvement of idiopathic aphthous ulcers with oral roflumilast therapy","volume":"187","author":"Gyldenl\u00f8ve","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0730","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1111\/jdv.18275","article-title":"Rapid clearing of refractory nummular dermatitis with oral roflumilast therapy","volume":"36","author":"Gyldenl\u00f8ve","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.01.009_bib0735","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ced\/llad041","article-title":"Severe and therapeutic challenging oral erosive lichen planus treated with oral roflumilast","volume":"48","author":"Fage","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0740","first-page":"llad189","article-title":"Refractory Beh\u00e7et's disease succesfully treated with Roflumilast","author":"Pe\u00f1uelas Leal","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0745","article-title":"Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO) - A Randomized Controlled Trial","author":"Thyssen","year":"2023","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0750","doi-asserted-by":"crossref","first-page":"e13060","DOI":"10.1111\/dth.13060","article-title":"Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey","volume":"32","author":"Maloney","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2024.01.009_bib0755","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/ajd.13253","article-title":"Improvement of recalcitrant Sneddon-Wilkinson disease with apremilast","volume":"61","author":"Magdaleno-Tapial","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0760","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/ced.14225","article-title":"Apremilast in benign chronic pemphigus (Hailey-Hailey disease)","volume":"45","author":"Riquelme-Mc Loughlin","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0765","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0770","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2012.07.014","article-title":"An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series","volume":"68","author":"Paul","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0775","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaad.2020.05.112","article-title":"Apremilast for the off-label treatment of lichenoid and interface dermatoses","volume":"83","author":"Ravichandran","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0780","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-013-0023-0","article-title":"Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases","volume":"3","author":"Wittmann","year":"2013","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2024.01.009_bib0785","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"Baughman","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0790","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","article-title":"Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages","volume":"76","author":"Maier","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2024.01.009_bib0795","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.11.009","article-title":"Apremilast as a treatment for morphea: A case series","volume":"19","author":"Koschitzky","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.ad.2024.01.009_bib0800","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaad.2022.01.015","article-title":"This Month in JAAD Case Reports: April 2022: Apremilast for Morphea","volume":"86","author":"Sloan","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.01.009_bib0805","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ad.2017.05.005","article-title":"Practical Management of Immunosuppressants in Dermatology","volume":"109","author":"Leis-Dosil","year":"2018","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.ad.2024.01.009_bib0810","doi-asserted-by":"crossref","first-page":"e12932","DOI":"10.1111\/dth.12932","article-title":"Biologics in dermatology: What does the future hold?","volume":"32","author":"Yavuz","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2024.01.009_bib0815","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2018.1466022","article-title":"Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States","volume":"29","author":"Wu","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2024.01.009_bib0820","unstructured":"EMA. Summary of product characteristics. European Medicines Agency. s. f."},{"key":"10.1016\/j.ad.2024.01.009_bib0825","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.116.232819","article-title":"Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes","volume":"358","author":"Dong","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ad.2024.01.009_bib0830","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/pharmaceutics15051556","article-title":"Pre-Clinical Assessment of Roflumilast Therapy in a Thoracic Model of Spinal Cord Injury","volume":"15","author":"Sousa","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ad.2024.01.009_bib0835","article-title":"Clinical Study to Evaluate the Possible Efficacy and Safety of Roflumilast in Patients With Ulcerative Colitis","year":"2023","journal-title":"clinicaltrials.gov;"},{"key":"10.1016\/j.ad.2024.01.009_bib0840","article-title":"Multi-Center Stage 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects With Nonalcoholic SteatoHepatitis","author":"AstraZeneca","year":"2016","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0845","article-title":"Efficacy of 500\u03bcg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Stage IIb, Proof of Concept Clinical Study","author":"AstraZeneca","year":"2016","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0850","article-title":"Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome","author":"Janez","year":"2014","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0855","article-title":"Efficacy of Roflumilast in Prevention of Peripheral Neuropathy","author":"Mansour","year":"2023","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ad.2024.01.009_bib0860","article-title":"Clinical Study Evaluating the Possible Efficacy and Safety of Roflumilast in Patients With Diabetic Nephropathy","author":"El-Nahhas","year":"2021","journal-title":"clinicaltrials.gov"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:17:56Z","timestamp":1757553476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0001731024000243"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.01.009","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.09.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}